TIL THERAPY IN CHINA:
MELANOMA, CERVICAL & LUNG CANCER
TIL therapy uses immune cells taken from a patient's own tumour, grown in large numbers in the lab, and given back to fight the cancer. China is one of the most active regions for TIL research โ particularly for melanoma, cervical cancer, and lung cancer. A responsible guide for patients exploring this option.
analyticsAt a Glance
- check_circleTIL therapy takes T lymphocytes from inside the patient's tumour โ cells that already recognise the cancer โ expands them to billions in a laboratory, and infuses them back.
- check_circleUnlike CAR-T, which targets a single antigen, TIL therapy uses a natural mix of immune cells recognising many tumour features โ potentially more effective for antigenically complex solid tumours.
- check_circleChina has active TIL research programmes for melanoma, cervical cancer, and non-small cell lung cancer โ with hospital-based trials at major oncology centres.
- check_circleAll TIL programmes in China are clinical trial-based โ eligibility requires individual review and patients must meet specific inclusion criteria before acceptance.
What Is TIL Therapy and How Does It Work?
Inside many solid tumours there are immune cells called T lymphocytes that have already recognised the cancer but are too few in number, or too exhausted, to control it. TIL therapy is built around these cells.
โTIL therapy asks the same question as all effective cancer immunotherapy: how do we give the immune system what it needs to finish what it started? The answer here is โ more of its own cells, in far greater numbers.โ
Step 1: Tumour Tissue Collection
A piece of tumour tissue is surgically removed โ typically through a biopsy or resection of an accessible lesion. The specimen goes to a specialised laboratory. Not all tumours yield sufficient TILs, so this step also functions as a quality check.
Step 2: TIL Expansion in the Laboratory
The T lymphocytes within the tumour are separated, activated, and grown into very large numbers โ typically billions of cells โ over several weeks. This is a technically demanding manufacturing process performed in specialist GMP laboratory facilities.
Step 3: Lymphodepletion Chemotherapy
Before infusion, the patient receives a short course of lymphodepleting chemotherapy โ typically fludarabine and cyclophosphamide. This clears existing immune cells to make space for the expanded TILs and reduces competition for the growth signals the new cells need.
Step 4: TIL Infusion and IL-2 Support
Billions of expanded TIL cells are infused. High-dose interleukin-2 (IL-2) is given to support survival and expansion of the infused cells. The IL-2 component causes significant systemic toxicity and requires close inpatient monitoring.
TIL Therapy in China: Active Research Areas
China has hospital-based TIL programmes and active clinical trials at several national cancer centres. The strongest evidence base and most active Chinese programmes cover three cancer types.
Melanoma
TIL therapy has its longest evidence history in melanoma โ where objective response rates of 30-40% have been reported in patients who have progressed on immunotherapy and targeted therapy. China's mucosal melanoma prevalence (higher than in Western populations) makes this a particularly relevant indication for Chinese TIL programmes, which include acral and mucosal subtypes not well-represented in Western trials.
Cervical Cancer
For patients with recurrent or metastatic cervical cancer after platinum-based chemotherapy and PD-1 immunotherapy, TIL therapy offers a cellular immune approach that targets the HPV-driven biology of this cancer. Chinese academic centres have active cervical cancer TIL studies โ a particularly relevant pathway given the high burden of cervical cancer in China and across South and Southeast Asia.
Non-Small Cell Lung Cancer
NSCLC is among the most immunogenic solid tumours โ making it a logical candidate for TIL therapy. Chinese trials are studying TIL in NSCLC patients who have progressed on PD-1 inhibitors and targeted therapy. Response rates in early studies are modest but represent a meaningful option for patients with limited alternatives.
TIL Therapy vs CAR-T: Key Differences
TIL and CAR-T are both adoptive cell therapies โ but they differ in important ways that determine which is appropriate for which patient.
TIL Therapy
- Targets many tumour antigens simultaneouslyUses a natural mix of T cells already recognising the patient's tumour โ less vulnerable to single-antigen escape.
- Better suited to solid tumoursParticularly studied in melanoma, cervical cancer, and lung cancer where CAR-T has shown less success.
- No genetic engineering requiredTILs are expanded, not reprogrammed โ manufacturing is complex but avoids viral vector engineering.
- Requires a tumour biopsyTILs must come from the patient's tumour โ a surgical collection step is required before expansion can begin.
CAR-T Cell Therapy
- Targets one specific antigen (e.g. CD19, BCMA)More precisely targeted but vulnerable to antigen loss โ most effective for blood cancers with defined surface markers.
- Strong evidence in blood cancersCD19 and BCMA CAR-T have Phase III RCT data in lymphoma, leukaemia, and myeloma.
- Genetic engineering of T cellsRequires viral vector transduction โ adds manufacturing complexity and regulatory considerations.
- No tumour biopsy neededT cells are collected from blood (leukapheresis) โ simpler collection than TIL's tumour tissue requirement.
Frequently Asked Questions
About TIL Therapy
Is TIL therapy approved in China?
TIL therapy remains investigational in China โ accessible through hospital-based clinical trials rather than as a routinely approved treatment. Lifileucel (Amtagvi) received FDA approval for melanoma in 2024, but its availability through commercial channels in China should be confirmed. Most patients in China access TIL through trial programmes at national cancer centres.
What makes a patient eligible for TIL therapy?
Key eligibility factors include: confirmed diagnosis of melanoma, cervical cancer, or NSCLC (depending on the trial); prior treatment with standard systemic therapy including immunotherapy; disease that is measurable by imaging; accessible lesion for tumour biopsy; adequate organ function; and performance status allowing tolerance of lymphodepletion chemotherapy and IL-2. Exact criteria vary by trial protocol.
What documents are needed for TIL eligibility review?
Pathology report confirming cancer type and subtype, full treatment history with response assessment, recent PET-CT or CT imaging, latest blood tests including organ function, any prior immunotherapy records, and documentation of current disease status. For melanoma, BRAF mutation status is relevant. For NSCLC, EGFR/ALK status and PD-L1 expression level should be included.
How long does TIL therapy require in China?
The complete TIL process from tumour collection to post-infusion monitoring typically requires 8-12 weeks in-country โ covering surgical collection, TIL manufacturing (3-6 weeks), lymphodepletion chemotherapy, infusion, and inpatient monitoring for IL-2 toxicity. Follow-up after discharge requires additional time before safe travel home.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Exploring TIL Therapy in China for Your Cancer?
Share your pathology, imaging, and treatment history โ our clinical team will assess whether an active TIL therapy trial in China is a realistic option for your specific diagnosis and prior treatment.
TIL therapy remains investigational in China. This information is for education and navigation support only โ not medical advice.